These results suggest that the spheroid system could constitute a valuable screening tool for active anti-NASH/fibrosis drug candidates based on the ability to reduce the deposition of COL1A1 and αSMA in this aggressively active phenotype. The gene discussed is COL1A1; the disease is metabolic dysfunction-associated steatohepatitis.